Arcturus Therapeutics Holdings Inc.
ARCT· Nasdaq
Released Mar 28, 2023, after the close
10-K filed Mar 29, 2023, 88 days after period end · 0000950170-23-010380
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021 | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $160.29M | $5.79M | $2.24M | $2.97M |
| Net Income | $117.35M | -$38.66M | -$31.10M | -$10.99M |
Arcturus Therapeutics Holdings Inc. · CIK 1768224 · Engraved from SEC EDGAR
| EPS Diluted | — | -$1.47 | -$1.25 | -$0.76 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.